메뉴 건너뛰기




Volumn 13, Issue 4, 2011, Pages 283-290

Treatment of lupus nephritis

Author keywords

Cyclophosphamide; Lupus nephritis; Mycophenolate mofetil; Systemic lupus erythematosus; Treatment

Indexed keywords

ABATACEPT; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; STEROID;

EID: 79960603712     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0187-5     Document Type: Review
Times cited : (6)

References (33)
  • 1
    • 0036158415 scopus 로고    scopus 로고
    • Systemic lupus erythematosus disease activity index 2000
    • DD Gladman D Ibañez MB Urowitz 2002 Systemic lupus erythematosus disease activity index 2000 J Rheum 29 2 288 291 11838846 (Pubitemid 34118775)
    • (2002) Journal of Rheumatology , vol.29 , Issue.2 , pp. 288-291
    • Gladman, D.D.1    Ibanez, D.2    Urowltz, M.B.3
  • 4
    • 0021153603 scopus 로고
    • Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome
    • HA Austin LR Muenz KM Joyce, et al. 1984 Diffuse proliferative lupus nephritis: identification of specific pathological features affecting renal outcome Kidney Int 25 689 695 6482173 10.1038/ki.1984.75 (Pubitemid 14079965)
    • (1984) Kidney International , vol.25 , Issue.4 , pp. 689-695
    • Austin III, H.A.1    Muenz, L.R.2    Joyce, K.M.3
  • 5
    • 78649873438 scopus 로고    scopus 로고
    • Updates on the treatment of lupus nephritis
    • 21051743 10.1681/ASN.2010050472 1:CAS:528:DC%2BC3MXktVeq
    • AS Bomback GB Appel 2010 Updates on the treatment of lupus nephritis J Am Soc Nephrol 21 2028 2035 21051743 10.1681/ASN.2010050472 1:CAS:528: DC%2BC3MXktVeq
    • (2010) J Am Soc Nephrol , vol.21 , pp. 2028-2035
    • Bomback, A.S.1    Appel, G.B.2
  • 6
    • 0022578857 scopus 로고
    • Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs
    • HA Austin JH Klippel JE Balow, et al. 1986 Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs N Engl J Med 314 10 614 619 3511372 10.1056/NEJM198603063141004 (Pubitemid 16132725)
    • (1986) New England Journal of Medicine , vol.314 , Issue.10 , pp. 614-619
    • Austin III, H.A.1    Klippel, J.H.2    Balow, J.E.3
  • 7
    • 0025786860 scopus 로고
    • Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only
    • 1859488 10.1002/art.1780340803 1:STN:280:DyaK3MzhsFKhug%3D%3D
    • AD Steinberg SC Steinberg 1991 Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only Arthritis Rheum 34 8 945 950 1859488 10.1002/art.1780340803 1:STN:280:DyaK3MzhsFKhug%3D%3D
    • (1991) Arthritis Rheum , vol.34 , Issue.8 , pp. 945-950
    • Steinberg, A.D.1    Steinberg, S.C.2
  • 9
    • 0029901773 scopus 로고    scopus 로고
    • 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis
    • G Moroni S Quaglini M Maccario, et al. 1996 "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis Kidney Int 50 2047 2053 8943489 10.1038/ki.1996.528 1:STN:280:DyaK2s%2FpvVyiug%3D%3D (Pubitemid 26417549)
    • (1996) Kidney International , vol.50 , Issue.6 , pp. 2047-2053
    • Moroni, G.1    Quaglini, S.2    Maccario, M.3    Banfi, G.4    Ponticelli, C.5
  • 10
    • 0141514427 scopus 로고    scopus 로고
    • Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome
    • M El Hachmi M Jadoul C Lefèbvre, et al. 2003 Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome Lupus 12 692 696 14514132 10.1191/0961203303lu444oa (Pubitemid 37173666)
    • (2003) Lupus , vol.12 , Issue.9 , pp. 692-696
    • El Hachmi, M.1    Jadoul, M.2    Lefebvre, C.3    Depresseux, G.4    Houssiau, F.A.5
  • 11
    • 0036673864 scopus 로고    scopus 로고
    • Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
    • 10.1002/art.10461
    • FA Houssiau C Vasconcelos D D'Cruz, et al. 2003 Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis Rheum 46 8 2121 2131 10.1002/art.10461
    • (2003) Arthritis Rheum , vol.46 , Issue.8 , pp. 2121-2131
    • Houssiau, F.A.1    Vasconcelos, C.2    D'Cruz, D.3
  • 14
    • 0034687429 scopus 로고    scopus 로고
    • Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
    • 11036121 10.1056/NEJM200010193431604 1:CAS:528:DC%2BD3cXnsleqs7w%3D
    • TM Chan FK Li CS Tang, et al. 2000 Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis N Engl J Med 343 16 1156 1162 11036121 10.1056/NEJM200010193431604 1:CAS:528:DC%2BD3cXnsleqs7w%3D
    • (2000) N Engl J Med , vol.343 , Issue.16 , pp. 1156-1162
    • Chan, T.M.1    Li, F.K.2    Tang, C.S.3
  • 15
    • 20444466207 scopus 로고    scopus 로고
    • Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis
    • DOI 10.1681/ASN.2004080686
    • TM Chan KC Tse CS Tang, et al. 2005 Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis J Am Soc Nephrol 16 4 1076 1084 15728784 10.1681/ASN.2004080686 1:CAS:528:DC%2BD2MXjsVWqtrc%3D (Pubitemid 41710318)
    • (2005) Journal of the American Society of Nephrology , vol.16 , Issue.4 , pp. 1076-1084
    • Chan, T.-M.1    Tse, K.-C.2    Tang, C.S.-O.3    Mok, M.-Y.4    Li, F.-K.5
  • 17
    • 34547830199 scopus 로고    scopus 로고
    • Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: A meta-analysis of randomized controlled trials
    • DOI 10.1093/ndt/gfm066
    • B Zhu N Chen Y Lin, et al. 2007 Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials Nephrol Dial Transplant 22 7 1933 1942 17405792 10.1093/ndt/gfm066 1:CAS:528:DC%2BD2sXos12htr0%3D (Pubitemid 47244763)
    • (2007) Nephrology Dialysis Transplantation , vol.22 , Issue.7 , pp. 1933-1942
    • Zhu, B.1    Chen, N.2    Lin, Y.3    Ren, H.4    Zhang, W.5    Wang, W.M.6    Pan, X.X.7    Yu, H.J.8
  • 18
    • 65649140169 scopus 로고    scopus 로고
    • Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
    • 19369404 10.1681/ASN.2008101028 1:CAS:528:DC%2BD1MXlvFKqt7w%3D This publication describes results of the international, randomized controlled clinical trial comparing MMF with IV CYC (ALMS trial). Patients responded similarly in both groups, and MMF was not shown to be superior to IV CYC as an induction treatment. It was also shown that the rates of adverse events, serious adverse events, and infections were not significantly different between the two groups.
    • GB Appel G Contreras MA Doolery, et al. 2009 Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis J Am Soc Nephrol 20 1103 1112 19369404 10.1681/ASN.2008101028 1:CAS:528:DC%2BD1MXlvFKqt7w%3D This publication describes results of the international, randomized controlled clinical trial comparing MMF with IV CYC (ALMS trial). Patients responded similarly in both groups, and MMF was not shown to be superior to IV CYC as an induction treatment. It was also shown that the rates of adverse events, serious adverse events, and infections were not significantly different between the two groups.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 1103-1112
    • Appel, G.B.1    Contreras, G.2    Doolery, M.A.3
  • 19
    • 0034045586 scopus 로고    scopus 로고
    • Mycophenolate mofetil and its mechanisms of action
    • DOI 10.1016/S0162-3109(00)00188-0, PII S0162310900001880
    • AC Allison EM Eugui 2000 Mycophenolate mofetil and its mechanisms of action Immunopharmacology 47 2-3 85 118 10878285 10.1016/S0162-3109(00)00188-0 1:CAS:528:DC%2BD3cXktlKkt7o%3D (Pubitemid 30394534)
    • (2000) Immunopharmacology , vol.47 , Issue.2-3 , pp. 85-118
    • Allison, A.C.1    Eugui, E.M.2
  • 20
    • 33847193118 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis
    • 17163990 10.1186/ar2093
    • RA Moore S Derry 2006 Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis Arthritis Res Ther 8 6 R182 17163990 10.1186/ar2093
    • (2006) Arthritis Res Ther , vol.8 , Issue.6 , pp. 182
    • Moore, R.A.1    Derry, S.2
  • 21
    • 77349120902 scopus 로고    scopus 로고
    • Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study
    • 19933596 10.1093/rheumatology/kep346
    • D Isenberg GB Appel G Contreras, et al. 2010 Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study Rheumatology 49 128 140 19933596 10.1093/rheumatology/kep346
    • (2010) Rheumatology , vol.49 , pp. 128-140
    • Isenberg, D.1    Appel, G.B.2    Contreras, G.3
  • 22
    • 75149150898 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): Results from the randomized, double-blind phase III LUNAR study [abstract]
    • R Furie RJ Looney B Rovin, et al. 2009 Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract] Arthritis Rheum 60 Suppl 10 1149
    • (2009) Arthritis Rheum , vol.60 , Issue.SUPPL. 10 , pp. 1149
    • Furie, R.1    Looney, R.J.2    Rovin, B.3
  • 23
    • 65249187242 scopus 로고    scopus 로고
    • A retrospective seven-year analysis of the use of B-cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients
    • 19333973 10.1002/art.24341
    • TY Lu KP Ng G Cambridge, et al. 2009 A retrospective seven-year analysis of the use of B-cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients Arthritis Rheum 61 4 482 487 19333973 10.1002/art.24341
    • (2009) Arthritis Rheum , vol.61 , Issue.4 , pp. 482-487
    • Lu, T.Y.1    Ng, K.P.2    Cambridge, G.3
  • 26
    • 79960606588 scopus 로고    scopus 로고
    • Treatment of lupus nephritis with enteric-coated mycophenolate sodium (EC-MPS)-MyLupus exploratory study [abstract]
    • A Doria 2010 Treatment of lupus nephritis with enteric-coated mycophenolate sodium (EC-MPS)-MyLupus exploratory study [abstract] Arthritis Rheum 62 10 S583
    • (2010) Arthritis Rheum , vol.62 , Issue.10 , pp. 583
    • Doria, A.1
  • 27
    • 79960463837 scopus 로고    scopus 로고
    • Aspreva Lupus Management Study (ALMS): Maintenance results [abstract]
    • As a continuation of the ALMS induction trial, MMF was compared with AZA as a maintenance regimen for LN patients who achieved response during the induction phase. MMF was found to be superior to AZA in maintaining renal remission.
    • EM Ginzler GB Appel MA Dooley, et al. 2010 Aspreva Lupus Management Study (ALMS): maintenance results [abstract] Arthritis Rheum 62 10 S871 S872 As a continuation of the ALMS induction trial, MMF was compared with AZA as a maintenance regimen for LN patients who achieved response during the induction phase. MMF was found to be superior to AZA in maintaining renal remission.
    • (2010) Arthritis Rheum , vol.62 , Issue.10
    • Ginzler, E.M.1    Appel, G.B.2    Dooley, M.A.3
  • 28
    • 78649751475 scopus 로고    scopus 로고
    • Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN nephritis trial
    • 20833738 10.1136/ard.2010.131995 1:CAS:528:DC%2BC3cXhs1emsb7F This study presented data comparing MMF with AZA after the ELNT induction regimen. The MMF group had fewer renal flares compared with the AZA group, but this difference was not statistically significant.
    • FA Houssiau D D'Cruz S Sangle, et al. 2010 Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial Ann Rheum Dis 69 2083 2089 20833738 10.1136/ard.2010.131995 1:CAS:528:DC%2BC3cXhs1emsb7F This study presented data comparing MMF with AZA after the ELNT induction regimen. The MMF group had fewer renal flares compared with the AZA group, but this difference was not statistically significant.
    • (2010) Ann Rheum Dis , vol.69 , pp. 2083-2089
    • Houssiau, F.A.1    D'Cruz, D.2    Sangle, S.3
  • 30
    • 5644258326 scopus 로고    scopus 로고
    • Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: An open-label study
    • DOI 10.1002/art.20576
    • M Aringer WB Graninger G Steiner JS Smolen 2004 Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study Arthritis Rheum 50 10 3161 3169 15476222 10.1002/art.20576 1:CAS:528:DC%2BD2cXpvFaisbY%3D (Pubitemid 39371992)
    • (2004) Arthritis and Rheumatism , vol.50 , Issue.10 , pp. 3161-3169
    • Aringer, M.1    Graninger, W.B.2    Steiner, G.3    Smolen, J.S.4
  • 32
    • 0026509147 scopus 로고
    • A controlled trial of plasma plasmapheresis therapy in severe lupus nephritis
    • 10.1056/NEJM199205213262101
    • EJ Lewis LG Lawrence S Lan, et al. 1992 A controlled trial of plasma plasmapheresis therapy in severe lupus nephritis N Engl J Med 21 326 1373 1379 10.1056/NEJM199205213262101
    • (1992) N Engl J Med , vol.21 , Issue.326 , pp. 1373-1379
    • Lewis, E.J.1    Lawrence, L.G.2    Lan, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.